アデュカヌマブ (Japanese Wikipedia)
Analysis of information sources in references of the Wikipedia article "アデュカヌマブ" in Japanese language version.
refsWebsite
Global rank
Japanese rank
low place
low place
34th place
255th place
7th place
63rd place
8,771st place
low place
719th place
3,311th place
99th place
542nd place
278th place
16th place
5th place
19th place
129th place
896th place
low place
low place
1,760th place
109th place
1st place
1st place
low place
low place
54th place
269th place
18th place
107th place
5,670th place
low place
low place
low place
low place
low place
low place
low place
low place
low place
5,344th place
low place
low place
low place
312th place
3,157th place
low place
low place
49th place
67th place
alz.org
- “It's a New Day in the Fight Against Alzheimer's — Aducanumab Approved”. Alzheimer's Association. 2021年6月11日閲覧。
alzfdn.org
- “Alzheimer's Foundation of America Statement on FDA Approving First New Alzheimer's Medication in Nearly 20 Years”. Alzheimer's Foundation of America. 2021年6月11日閲覧。
alzheimer.ca
- “First new treatment for Alzheimer's disease approved in nearly two decades offers hope for people living with dementia”. Alzheimer Society of Canada (2021年6月7日). 2021年6月11日閲覧。
apnews.com
- Marchione, Marilynn; Perrone, Matthew (2020年11月6日). “FDA panel urges rejection of experimental Alzheimer's drug”. Associated Press
bbc.co.uk
- Roberts, Michelle (2019年10月22日). “First drug to slow Alzheimer's may be available soon”. BBC News 2019年10月22日閲覧。
bbc.com
- Foster, Laura (2019年10月26日). “Drug 'could be biggest Alzheimer's development'”. BBC News. 2019年10月26日閲覧。
- “US approves first new Alzheimer's drug in 20 years”. (2021年6月7日)
bcbsm.com
- How do drug tiers work?. Blue Cross Blue Shield of Michigan. Retrieved 14 June 2021.
biogen.com
investors.biogen.com
- “Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies”. Biogen (2019年10月22日). 2019年10月22日閲覧。
bloomberg.com
- Langreth, Robert (2021年6月10日). “Harvard Expert Quits FDA Panel as Furor Over Biogen Drug Grows”. Bloomberg 2021年6月10日閲覧。
- Edney, Anna (2021年6月17日). “Key Democrat Manchin Bashes FDA Leader on Alzheimer's Approval”. Bloomberg News
bloomberglaw.com
news.bloomberglaw.com
- Annett, Timothy. “Biogen Plunges More Than 25 Percent on Alzheimer's Setback”. Bloomberg News. 2021年6月23日閲覧。
bmj.com
- “Three FDA advisory panel members resign over approval of Alzheimer’s drug”BMJ（11 June 2021）2021年8月15日閲覧
citizen.org
- “Statement: FDA's Decision to Approve Aducanumab for Alzheimer's Disease Shows Reckless Disregard for Science, Severely Damages Agency's Credibility”. Public Citizen (2021年6月7日). 2021年6月11日閲覧。
cms.gov
- National Coverage Analysis (NCA) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N). September 27, 2013. Centers for Medicare & Medicaid Services (CMS). Retrieved 19 June 2021.
cnbc.com
- “Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug”CNBC（JUN 10 2021）2021年8月15日閲覧
- “Biogen stock falls after FDA calls for federal investigation into Alzheimer’s drug approval”CNBC（JUL 9 2021）2021年8月15日閲覧
- Li, Yun (2019年3月21日). “Biogen shares plunge nearly 30% after ending trial for Alzheimer's drug Aducanumab”. CNBC
- Li, Yun (2019年3月21日). “Biogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drug”. CNBC. 2021年6月23日閲覧。
cnn.com
edition.cnn.com
- “Drugmaker to seek approval for Alzheimer's treatment”. CNN (2019年10月23日). 2019年10月23日閲覧。
dddmag.com
- Fox, Cynthia (2015年4月28日). “The Story of Biogen's Alzheimer's Drug, Aducanumab”. Drug Discovery and Development. 2015年7月1日時点のオリジナルよりアーカイブ。2021年6月23日閲覧。
doi.org
- Toyn J (May 2015). “What lessons can be learned from failed Alzheimer's disease trials?”. Expert Review of Clinical Pharmacology 8 (3): 267–9. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (September 2016). “The antibody aducanumab reduces Aβ plaques in Alzheimer's disease”. Nature 537 (7618): 50–6. Bibcode: 2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220.
- Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK (October 2020). “Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease”. Curr Neuropharmacol 18 (9): 883–903. doi:10.2174/1570159X18666200429011823. PMC 7569315. PMID 32348223.
fda.gov
fda.gov
- "FDA Grants Accelerated Approval for Alzheimer's Drug". U.S. Food and Drug Administration (FDA) (Press release). 7 June 2021. 2021年6月7日閲覧。
この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。 - “FDA's Decision to Approve New Treatment for Alzheimer's Disease”. U.S. Food and Drug Administration (FDA) (2021年6月7日). 2021年6月7日閲覧。
accessdata.fda.gov
forbes.com
- Herper, Matthew (2015年3月20日). “Biogen Drug Could Inspire New Hope For Alzheimer's Treatments”. Forbes
gendai.media
- “悲願「アルツハイマー型認知症新薬」、日本人はまだまだ知らない「理想」と「現実」（村上 和巳） @moneygendai”. マネー現代. 2021年7月4日閲覧。
harvard.edu
ui.adsabs.harvard.edu
- Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (September 2016). “The antibody aducanumab reduces Aβ plaques in Alzheimer's disease”. Nature 537 (7618): 50–6. Bibcode: 2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220.
icer.org
- “ICER Issues Statement on the FDA's Approval of Aducanumab for Alzheimer's Disease”. ICER. 2021年6月11日閲覧。
mainichi.jp
- アルツハイマー病新薬、実像は(上) 夢のような根治、期待できず『毎日新聞』朝刊2021年7月22日くらしナビ面（2021年8月15日閲覧）
medicare.gov
- What Medicare Part D drug plans cover. US Centers for Medicare & Medicaid Services. Retrieved 14 June 2021.
medscape.com
- McNamara, Damien (2020年5月28日). “Mixed Results for Aducanumab in Two Phase 3 AD Trials”. Medscape. 2021年6月23日閲覧。
- Ault, Alicia (2021年5月5日). “FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer's”. Medscape Medical News. 2021年6月9日閲覧。
newchoicehealth.com
- How much does a PET scan cost?. 2018-07-31. New Choice Health. Retrieved 19 June 2021
nih.gov
pubmed.ncbi.nlm.nih.gov
- Toyn J (May 2015). “What lessons can be learned from failed Alzheimer's disease trials?”. Expert Review of Clinical Pharmacology 8 (3): 267–9. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (September 2016). “The antibody aducanumab reduces Aβ plaques in Alzheimer's disease”. Nature 537 (7618): 50–6. Bibcode: 2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220.
- Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK (October 2020). “Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease”. Curr Neuropharmacol 18 (9): 883–903. doi:10.2174/1570159X18666200429011823. PMC 7569315. PMID 32348223.
ncbi.nlm.nih.gov
- Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK (October 2020). “Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease”. Curr Neuropharmacol 18 (9): 883–903. doi:10.2174/1570159X18666200429011823. PMC 7569315. PMID 32348223.
pmc.ncbi.nlm.nih.gov
- Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK (October 2020). “Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease”. Curr Neuropharmacol 18 (9): 883–903. doi:10.2174/1570159X18666200429011823. PMC 7569315. PMID 32348223.
npr.org
- “3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval”. (2021年6月11日) 2021年6月11日閲覧。
- “Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually”. NPR (2021年6月10日). 2021年6月11日閲覧。
nytimes.com
- Belluck, Pam; Robbins, Rebecca (2021年6月10日). “Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug”. The New York Times. ISSN 0362-4331 2021年6月14日閲覧。
- Belluck, Pam; Robbins, Rebecca (2021年6月5日). “Alzheimer's Drug Poses a Dilemma for the F.D.A.”. The New York Times 2021年6月7日閲覧。
- Belluck P, Robbins R (2021年6月7日). “F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works”
politico.com
- New Alzheimer's drug could be 'devastating' for Medicare 06/15/2021. Politico. Retrieved 19 June 2021.
seekingalpha.com
statnews.com
- Karlawish, Jason (2021年5月30日). “If the FDA approves Biogen's Alzheimer's treatment, I won't prescribe it”. STAT 2021年6月7日閲覧。
- Herper, Matthew (2019年10月22日). “In shocking reversal, Biogen to submit Alzheimer's drug for approval”. STAT. 2019年10月22日閲覧。 “"In one study, called Emerge, patients on the high-dose aducanumab had a 23% reduction in their rate of decline compared to those on placebo; those who were on the low dose were 11% lower than placebo, but that result was not statistically significant. But in the second trial, Engage, the decrease was only 2% in patients on the high dose."”
time.com
- Ducharme, Jamie (2019年3月21日). “Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results”. Time. 2019年3月21日閲覧。
washingtonpost.com
- McGinley, Laurie (2021年6月22日). “FDA releases fresh details on internal debate over controversial Alzheimer's drug”
- Kunkle, Fredrick (2019年12月6日). “Biogen's potential new drug for Alzheimer's disease gets cautiously optimistic review following presentation”. The Washington Post
- McGinley, Laurie (2021年6月17日). “Furor rages over FDA approval of controversial Alzheimer's drug” 2021年6月19日閲覧。
- McGinley, Laurie (2021年6月9日). “Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug”. The Washington Post. 2021年6月9日閲覧。
web.archive.org
- Fox, Cynthia (2015年4月28日). “The Story of Biogen's Alzheimer's Drug, Aducanumab”. Drug Discovery and Development. 2015年7月1日時点のオリジナルよりアーカイブ。2021年6月23日閲覧。
wikipedia.org
en.wikipedia.org
- "FDA Grants Accelerated Approval for Alzheimer's Drug". U.S. Food and Drug Administration (FDA) (Press release). 7 June 2021. 2021年6月7日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
- “FDA's Decision to Approve New Treatment for Alzheimer's Disease”. U.S. Food and Drug Administration (FDA) (2021年6月7日). 2021年6月7日閲覧。
- How do drug tiers work?. Blue Cross Blue Shield of Michigan. Retrieved 14 June 2021.
- What Medicare Part D drug plans cover. US Centers for Medicare & Medicaid Services. Retrieved 14 June 2021.
- “Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually”. NPR (2021年6月10日). 2021年6月11日閲覧。
- National Coverage Analysis (NCA) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N). September 27, 2013. Centers for Medicare & Medicaid Services (CMS). Retrieved 19 June 2021.
- New Alzheimer's drug could be 'devastating' for Medicare 06/15/2021. Politico. Retrieved 19 June 2021.
worldcat.org
search.worldcat.org
- Belluck, Pam; Robbins, Rebecca (2021年6月10日). “Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug”. The New York Times. ISSN 0362-4331 2021年6月14日閲覧。
wsj.com
xconomy.com
- Zacks, Rebecca (2007年11月20日). “Biogen Inks $380 Million Deal with Swiss Company”. Xconomy. 2021年6月23日閲覧。